New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

Baptist Gallwitz
Dept Medicine IV, Tübingen University, Otfried-Müller-Str, 10, 72076 Tübingen, Germany

Abstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It is highly selective for DPP-4 in comparison to other enzymes of the dipeptidyl peptidase family. DPP-4 inhibitors elevate plasma concentrations of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This effect results in a glucose-dependent stimulation of insulin secretion and an inhibition of glucagon secretion without an intrinsic risk for hypoglycemia. In comparison to sulfonylureas and thiazolidinediones that promote weight gain, DPP-4 inhibitors are weight neutral. Saxagliptin has been approved by the FDA for the US and by the EMEA for Europe in 2009. Clinical trials showed a dose-dependent inhibition of DPP-4 by saxagliptin in doses ranging from 2.5 to 100 mg daily without serious side effects. Type 2 diabetic patients receiving 5 mg to 10 mg saxagliptin once daily had a significant lowering of HbA1c and glycemic parameters along with good tolerability and safety. Saxagliptin has demonstrated a good efficacy for glycemic parameters in various patient populations either in monotherapy or in combination with metformin and other oral antidiabetic drugs as well as a favorable cardiovascular profile. With its high selectivity for DPP-4 and its clinical and cardiovascular profile, saxagliptin is an attractive novel DPP-4 inhibitor.

Keywords: type 2 diabetes, diabetes therapy, DPP-4 inhibitors, incretin based therapy, GLP-1, saxagliptin

Introduction
The prevalence of type 2 diabetes is increasing dramatically worldwide. Estimations by the International Diabetes Federation (IDF) forecast the total number of people with diabetes to be 440 million worldwide by the year 2030. The increase in type 2 diabetes prevalence will inevitably lead to an increase of the complications and comorbidities of this disease. Efficacious and safe treatment options for type 2 diabetes are needed to prevent hypoglycemia and diabetes-related complications.

The pathophysiology of type 2 diabetes mainly comprises two phenomena: insulin resistance and a disturbance of insulin secretion. While insulin resistance is fairly constant in the time course of type 2 diabetes, the disturbance in insulin secretion worsens during the course of the disease due to continuously declining islet function. Decreasing islet function is the driving force for type 2 diabetes disease progression. This development is aggravated by chronically persisting hyperglycemia, elevated plasma concentrations of free fatty acids, cytokines, adipokines and toxic metabolic products that are detrimental for islet function and finally lead to a loss of beta-cell mass. The glucagon-secreting alpha cells in the islet additionally develop a
secretory defect. In nondiabetes people, glucagon secretion is suppressed during hyperglycemia, but in type 2 diabetes subjects glucagon secretion during hyperglycemic conditions does not become suppressed. The relative hyperglucagonemia is possibly causal to the excessive glucose production by the liver observed in type 2 diabetes.\(^2\)\(^-\)\(^5\)

The older treatment options for type 2 diabetes are limited and do not address the problem of islet-cell dysfunction. Classical insulin secretagogues (sulfonylureas and glinides) exclusively act on the beta-cell and stimulate insulin secretion, but do not address the secretion defect of the alpha cells. Metformin and thiazolidinediones have a beneficial influence on insulin resistance, but have important contraindications. These are impaired renal function for metformin and heart failure for thiazolidinediones. The therapy with thiazolidinediones leads to an undesired gain in body weight. Alpha-glucosidase inhibitors delay the breakdown of complex carbohydrates and therefore act mainly on postprandial metabolism. With insulin therapy, a relative lack of insulin can be replaced and the endogenous secretory insulin deficit can be overcome, but insulin therapy is associated with a risk for hypoglycemia and weight gain. The increasing loss of islet function characterizing type 2 diabetes is not ameliorated by any of the classical treatment options.\(^2\)\(^-\)\(^5\)

In the past few years, incretin-based therapies have become available offering promising ways to overcome the limitations of the classical treatment options for type 2 diabetes described above.

The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are secreted after a meal from the intestinal L- and K-cells respectively and physiologically stimulate insulin secretion postprandially. They are responsible for the incretin effect that described the phenomenon that orally ingested glucose evokes a greater insulin response than an intravenously administered glucose infusion calculated to lead to identical serum glucose excursions.\(^6\)\(^-\)\(^8\)

The physiology of GLP-1 and its possible promising role as a pharmacological tool for treating type 2 diabetes was first described in the late 1990s. In contrast to the classical insulinotropic agents (sulfonylureas and glinides), the insulinotropic action of GLP-1 is strictly glucose dependent. GLP-1 stimulates insulin secretion only during hyperglycemia. This effect provides the possibility of glucose normalization without the risk of hypoglycemia. In patients with type 2 diabetes with hyperglycemia, exogenous parenteral GLP-1 application stimulates insulin secretion and normalizes both fasting and postprandial blood glucose. GLP-1 is also able to restore the defective first phase of insulin secretion in type 2 diabetes.\(^2\)

Besides these antihyperglycemic effects, GLP-1 also possesses additional noninsulinotropic physiological actions that are attractive for type 2 diabetes treatment: GLP-1 suppresses glucagon secretion from the alpha-cells also in a glucose dependent manner. Under hyperglycemic conditions, glucagon secretion is inhibited, while under hypoglycemia, glucagon secretion is even increased. The latter effect also contributes to the low hypoglycemia risk with GLP-1 based therapies.\(^2\)\(^,\)\(^9\)

Furthermore, GLP-1 slows gastric emptying and gastrointestinal motility. It also acts as a mediator of satiety in the hypothalamus, where it is an important neurotransmitter.\(^2\)\(^,\)\(^5\)

These two actions are responsible for the observation that in healthy subjects and type 2 diabetes patients GLP-1 infusions lead to decreased caloric intake and consecutively weight loss.\(^10\)\(^,\)\(^11\)

GLP-1 has beneficial effects on beta-cell function and mass by stimulating beta-cell formation from precursor cells and inhibiting beta-cell apoptosis.\(^2\)\(^,\)\(^11\)\(^,\)\(^12\)

Dipeptidyl peptidase-4 (DPP-4) is the enzyme that is responsible for the degradation of GLP-1 resulting in its short biological half-life of only 1–2 minutes. Due to the extremely short biological half-life, treatment with native GLP-1 is not feasible. In order to use GLP-1 effects as therapeutic principle, long-acting GLP-1 receptor agonists have been developed as an injectable therapy. The other alternative to utilize GLP-1 action is the inhibition of the degrading enzyme DPP-4 by orally active DPP-IV inhibitors.\(^2\)\(^,\)\(^13\)

DPP-4 is a ubiquitous enzyme and is found in the endothelium of various organs as well as measurable circulating enzymatic activity in plasma in soluble form. Besides GLP-1 many other peptides are substrates of DPP-4, but the affinity towards GLP-1 is predominant. DPP-4 cleaves and inactivates GLP-1 within a few minutes.\(^14\)

DPP-4 is also expressed on the cell membrane of activated T-lymphocytes where it was first described as CD26 receptor.\(^15\) The enzymatic functions and the active center of DPP-4 are, however, localized in a distant part of the molecule in respect to the CD26 receptor function. An influence of DPP-4 inhibitors on immunological CD26 mediated functions is therefore not expected and unlikely. The broad clinical use of DPP-4 inhibitors has so far not revealed serious side effects or adverse events on immunological regulatory mechanisms.\(^2\)

DPP-4 inhibition promotes an attractive therapeutic principle by increasing plasma concentrations of endogenous GLP-1. While GLP-1 receptor agonists are injectable compounds, DPP-4 inhibitors are orally active.\(^2\) DPP-4 belongs to the enzyme family of endopeptidases. DPP-4...
inhibitors must therefore have a high selectivity to inhibit only DPP-4 and not other DPPs. The DPP-4 inhibitors sitagliptin and vildagliptin have already been approved in many countries and have been shown to be efficacious and safe due to their DPP-4 selectivity.\textsuperscript{15,16} Saxagliptin, a novel DPP-4 inhibitor, was developed by AstraZeneca and Brystol-Myers Squibb and has just been approved (trade name Onglyza®). Further DPP-4 inhibitors such as alogliptin, dutaglitin and linagliptin are in development.\textsuperscript{17,18}

**Development, synthesis and preclinical pharmacology of saxagliptin**

In the development of DPP-4 inhibitors, a long duration of action was a desirable feature. Compounds with a vinyl substitution at the 4-position of \( \alpha \)-cycloalkyl-substituted glycines and their oxygenated metabolites did not lead to a loss of potency, but to a desired increase in duration of action.\textsuperscript{19,20} Consecutive exploration of molecules with an hydroxylated adamantyl group led to saxagliptin, that is characterized by a high \textit{in vitro} and \textit{in vivo} potency, good oral bioavailability (\( F = 75\% \)), good duration of action (\( t/2 = 2.1 \) hours) and no CYP3A4 inhibition.\textsuperscript{20–22} Saxagliptin interacts with DPP-4 at the Ser630 residue in the active center of DPP-4. The formation of the covalent complex of saxagliptin and DPP-4 is reversible, with a dissociation constant (\( k_{\text{off}} \)) of 5.5 \( \times 10^{-5} \) \( \text{s}^{-1} \) and an equilibrium constant \( K_i^* \) (as \( k_{\text{off}}/k_{\text{on}} \)) for the formation of the covalent intermediate of 0.35 nM. This value is similar to the value obtained from steady-state inhibition studies of 0.6 nM.\textsuperscript{21,24,25}

Saxagliptin has a very high selectivity for DPP-4 and its \textit{in vitro} potency shows a 400- and 75-fold higher potency versus DPP-4 than for DPP-8 or DPP-9, respectively. It also demonstrates a more than 4000-fold greater potency for DPP-4 in comparison to a number of other proteases. Saxagliptin possesses a dissociation constant for inhibitor binding (\( K_i \)) of 1.3 \( \pm 0.3 \) nM for inhibiting DPP-4, making it 10- to 14-fold more potent than vildagliptin (13 \( \pm 3 \) nM) and sitagliptin (18 \( \pm 2 \) nM), respectively.\textsuperscript{26}

\textit{In vivo} saxagliptin has an \( IC_{50} \) value for DPP-4 inhibition of 30 nM and \( ED_{50} \) values at 0.5 and 6 hours were attained with saxagliptin at 0.1 and 0.5 \( \mu \)mol/kg, respectively, demonstrating a good activity over time and long duration. A significant rise of endogenous GLP-1 was observed after an oral glucose challenge in healthy rats with a saxagliptin dose of 3 \( \mu \)mol/kg and no inhibition of T-cell activity was detected.\textsuperscript{20,21}

The \textit{in vivo} DPP-4 inhibitory activity in Sprague-Dawley rats was 87%. The \( K_i \) value was 0.6 \( \pm 0.06 \) nM, the \( ED_{50} \) values at 0.5, 2, 4 and 6 hours post-administration were 0.12 \( \pm 0.04 \), 0.2 \( \pm 0.07 \), 0.3 \( \pm 0.10 \) and 0.5 \( \pm 0.15 \) \( \mu \)mol/kg, respectively. In a diabetes, insulin-resistant rat model, saxagliptin (0.3 to 3 \( \mu \)mol/kg po) improved glucose clearance by 28%–61% relative to controls at 2 hours after glucose challenge. Saxagliptin was also effective at raising insulin levels and increasing glucose clearance in ob/ob mice at 1, 3 or 10 \( \mu \)mol/kg po.\textsuperscript{24}

In man, the \( IC_{50} \) for DPP-4 inhibition by saxagliptin is 30 nM, the \( ED_{50} \) 0.5 and 6 hours after a single dose are 0.1 and 0.5 \( \mu \)mol/kg, respectively. Therefore, saxagliptin has sufficient activity over time for once daily dosing. Saxagliptin is metabolized in humans forming an active metabolite. The active metabolite BMS-510849 is 2-fold less potent than saxagliptin. The endogenous GLP-1 concentrations rise 1.5- to 3.0-fold after oral administration of saxagliptin.\textsuperscript{21,27} Pharmacokinetic and pharmacodynamic properties of saxagliptin were investigated in healthy subjects at doses up to 400 mg daily and in type 2 diabetes patients in doses from 2.5 mg to 50 mg od. The maximally DPP-4 inhibiting effect of saxagliptin was observed at a single dose of 150 mg. Percentages of DPP-4 inhibition 24 hours post-dose for 2.5 mg and 400 mg saxagliptin were 50% and 79% of the predose activity, respectively. Doses of 400 mg od saxagliptin for 2 weeks were safe and well tolerated.\textsuperscript{21,28} So far, no specific drug–drug interactions were detected for saxagliptin and other commonly used medications.\textsuperscript{29–32}

**Clinical studies with saxagliptin**

Phase 1 studies showed a dose dependent DPP-4 inhibition in a dose range from 2.5 to 100 mg saxagliptin given once daily. In a large phase 2 study in drug-naive patients (\( n = 350 \)) with inadequately controlled type 2 diabetes saxagliptin was given in doses of 2.5, 5, 10, 20 or 40 mg/day po for 12 weeks or 100 mg/day po for 6 weeks. The baseline HbA1c ranged from 6.8%–9.7%. In the placebo group, 20% of patients achieved HbA1c levels of <7.0%, compared with 50%, 47%, 41%, 50%, 53% and 66% of patients in the saxagliptin groups, respectively. Fasting plasma glucose and post-challenge glucose after a liquid meal were also dose dependently and significantly improved by saxagliptin.\textsuperscript{21,28,33} A subsequent phase 2B/phase 3 study investigated saxagliptin as add-on to metformin. Patients on a stable dose of metformin (1500–2550 mg/day) and a baseline HbA1c 7.0%–10.0% were enrolled. Saxagliptin was tested against placebo at doses of 2.5, 5 or 10 mg od administered as add-on to metformin. A total of 743 patients participated
in this 24-week trial. Saxagliptin led to a decrease in HbA1c compared to placebo of −0.73%, −0.83% and −0.71% from a baseline of 8.0 ± 0.9% for the 2.5, 5 or 10 mg dose after 24 weeks, respectively (P < 0.0001). The fasting plasma glucose also significantly decreased by −16, −24 and −21 mg/dL from a baseline of 176 ± 46 mg/dL (P < 0.0001). In oral glucose tolerance tests, saxagliptin significantly improved glycemic excursions and reduced the glucose and glucagon AUCs while increasing the AUCs for insulin and C-peptide. The therapy with saxagliptin was well tolerated and the incidence of hypoglycemic events was on placebo level. The treatment with saxagliptin was weight neutral (body weight change of −1.5, −0.9, −0.5, and −1.0 kg for 2.5, 5, and 10 mg saxagliptin and placebo, respectively).34

The study program leading to the approval of saxagliptin was extensive. Figure 1 shows the phase 3 program of the clinical studies and the number of patient’s involved.34-38 A dose-range study in drug naïve type 2 diabetic patients with an HbA1c of 6.8%–9.7% (mean 7.9%) at baseline were treated with saxagliptin in a dose range from 2.5 mg to 40 mg once daily. The treatment with saxagliptin led to a dose-dependent placebo subtracted reduction in HbA1c by 0.45%–0.63%. The fasting- and postprandial plasma glucose concentrations were also lowered dose-dependently by saxagliptin. The drug did not cause hypoglycemia, was well tolerated and was weight neutral as in other studies.36,39

An initial combination therapy with saxagliptin plus metformin versus saxagliptin or metformin monotherapy lasting 24 weeks demonstrated that saxagliptin 5 mg plus metformin and saxagliptin 10 mg plus metformin demonstrated statistically significant decreases in glycemic parameters. The aim of this study was to evaluate the efficacy and safety of an initial combination treatment with saxagliptin plus metformin and compare it to a saxagliptin- or metformin monotherapy in treatment-naïve patients with type 2 diabetes and inadequate glycemic control. A total of 1306 patients were enrolled in this 24-week study. At the end of the trial, the proportion of patients reaching an HbA1c goal <7% was 60.3% and 59.7% for saxagliptin 5 mg plus metformin and saxagliptin 10 mg plus metformin, respectively (all P < 0.0001 vs monotherapy). The incidence of adverse events was comparable in all groups and the overall rate of hypoglycemic episodes was very low on placebo level.38

As add-on therapy in patients treated with a sulfonylurea, saxagliptin, when added to a submaximal dose of glyburide, improved glycemic parameters significantly and was superior to up titrating the sulfonylurea. In this study, a total of 768 patients were randomized to receive 2.5 mg or 5 mg in combination with glyburide 7.5 mg or glyburide 10 mg as monotherapy for 24 weeks. At the end of the study, 92% of patients on glyburide monotherapy were up titrated to a total glyburide dose of 15 mg/day, corresponding to the maximal dose allowed according to the study protocol. Saxagliptin at the doses of 2.5 mg and 5 mg od provided statistically significant adjusted mean decreases of HbA1c from baseline to week 24 vs up titrated glyburide of −0.54%, −0.64% vs +0.08%, respectively (both P < 0.0001). Other glycemic parameters (fasting plasma glucose, postprandial glucose, proportion of patients reaching an HbA1c goal <7%) were significantly better in the groups receiving saxagliptin. Reported hypoglycemic events were not statistically significantly different for saxagliptin 2.5 mg (13.3%) and 5 mg (14.6%) vs up titrated glyburide (10.1%) and the incidence of adverse events was similar in all groups.37

The efficacy and safety of saxagliptin were also investigated in a study using saxagliptin as an add on to a pre-existing therapy with glitazones in type 2 diabetic patients with a baseline HbA1c of 7.0%–10.5%. A total of 565 patients receiving stable glitazone monotherapy (pioglitazone 30 mg or 45 mg or rosiglitazone 4 mg or 8 mg od) were treated with either 2.5 mg or 5 mg saxagliptin or placebo as add-on for 24 weeks. Both doses of saxagliptin (2.5 mg and 5 mg) as add-on to a glitazone led to statistically significant adjusted mean decreases in HbA1c vs placebo (−0.66% and −0.94% for saxagliptin 2.5 mg and 5 mg vs −0.30% for placebo). Fasting plasma glucose, postprandial glucose and the proportion of patients reaching an HbA1c goal <7% were significantly improved in the saxagliptin treated patients. Saxagliptin was generally well tolerated; adverse event occurrence and reported hypoglycemic events were similar across all groups.40

A study assessing the efficacy of 5 mg saxagliptin daily used different insulin secretion parameters after 12 weeks as efficacy measures in 156 patients not well controlled with diet and exercise (HbA1c between 6.0% and 8.0%).21,28,33 A study in patients with impaired renal function (creatinine clearance <50 mL/min) is still ongoing and investigating the efficacy and safety of 2.5 mg saxagliptin given od.21,28,33 A study in 18 patients with hepatic impairment (Child–Pugh Score A–C) compared the pharmacokinetics of 10 mg saxagliptin to a healthy control group. A higher elevation of AUC values after saxagliptin (10%–77% higher) was observed in the patients with hepatic impairment. Correspondingly, the AUC values for the metabolite were 7%–33% lower, depending on the severity of hepatic impairment. These results indicate a reduced capacity to metabolize the drug with increasing
Saxagliptin for type 2 diabetes therapy

Table 1: Monotherapy studies with saxagliptin

<table>
<thead>
<tr>
<th>Dose (mg)</th>
<th>Placebo</th>
<th>Saxagliptin (mg)</th>
<th>Placebo</th>
<th>Saxagliptin (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>QAM</td>
<td>QAM</td>
<td>QAM</td>
<td>QPM</td>
</tr>
<tr>
<td>2.5</td>
<td>5</td>
<td>2.5/5</td>
<td>5</td>
<td>68</td>
</tr>
<tr>
<td>5</td>
<td>5</td>
<td>2.5/5</td>
<td>5</td>
<td>68</td>
</tr>
<tr>
<td>10</td>
<td></td>
<td>2.5/5</td>
<td>5</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>92</td>
<td>67</td>
<td>69</td>
<td>70</td>
</tr>
<tr>
<td>Basal mean HbA1c (%)</td>
<td>7.91</td>
<td>7.98</td>
<td>7.85</td>
<td>7.88</td>
</tr>
</tbody>
</table>

Notes: For HbA1c changes, see Figure 2.

Abbreviations: QAM, every morning; QPM, every afternoon.
a higher incidence of specific adverse events compared to
the placebo group.39 Possible drug–drug interactions with
saxagliptin were also examined extensively and did not give
a signal for drug-drug interactions between saxagliptin and
common medications.21,29–32 In patients with renal or hepatic
impairment, additional data have to be obtained to be able
to evaluate the safety and efficacy of saxagliptin in these
patient groups. One study in patients with renal impairment
is still ongoing. In hepatic organ dysfunction, dose reductions
to lower doses seem to be feasible without additional side
effects. Saxagliptin was well tolerated in a small study such
patients receiving a single saxagliptin dose.41

Discussion and perspectives
DPP-4 inhibitors have been introduced into type 2 diabetes
therapy in 2006 with sitagliptin as first substance,16 followed
by vildagliptin15 and now saxagliptin in 2009. The DPP-4
inhibitors are the first substances having a glucose-dependent
dual action on alpha- and beta-cell function stimulating
insulin secretion and suppressing glucagon secretion under
hyperglycemic conditions. This dual action leads to an
improved time course of islet hormone secretion after a
meal and in hyperglycemia. The glucose-dependent action
results in a hypoglycemia risk that is comparable to placebo
treatment. On the other hand, hormonal counter-regulation in
hypoglycemia is not impaired, but actually improved.42 Animal
studies and in vitro data from isolated human islets suggest
that DPP-4 inhibitors increase beta-cell function and mass.
These findings may support the hypothesis that DPP-4 inhibitors
as well as a therapy with GLP-1 analogs have a beneficial
effect on disease progression of type 2 diabetes.17,18 Clinical
studies with saxagliptin have demonstrated very satisfactory
data on the improvement of glycemic parameters together
with a good safety profile and good tolerability over a time
range up to 24 weeks in clinical studies in a large cohort of
patients.21,28,33–39,41,43 (see Tables 1 and 2, Figure 2). In com-
parison to other sitagliptin and vildagliptin, saxagliptin shows
a similar efficacy and safety profile in monotherapy as well
as in the initial combination with metformin or as add-on
to metformin or a glitazone.21,28,33–40 Additional studies also
showed that there is no serious drug–drug interaction with
other common medications often taken by type 2 diabetic
patients, eg, antacids, anticoagulants and digitoxin.29–32 A small
study investigating the pharmacokinetics of saxagliptin in
patients with hepatic impairment demonstrated a slower
metabolization of saxagliptin, but no severe side effects.41

Table 2 Add on combination therapy studies with saxagliptin

<table>
<thead>
<tr>
<th>Dose</th>
<th>PBO + MET</th>
<th>PBO + TZD</th>
<th>PBO + SU</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.5 mg</td>
<td>5 mg</td>
<td>5 mg</td>
<td>5 mg</td>
</tr>
</tbody>
</table>

n = 186 186 180 175 192 183 180 246 250 264

Basal mean HbA1c (%) 8.08 8.07 7.98 8.06 8.25 8.35 8.19 8.36 8.48 8.44

Notes: For HbA1c changes, see Figure 2

Abbreviation: SAXA, saxagliptin; MET, metformin; TZD, thiazolidinedione; PBO, placebo; GLY, glyburide.

Figure 2 Pooled data of the HbA1c reductions observed in the clinical studies with saxagliptin (SAXA):34–36,38–40 The left hand side of the figure shows the pooled monotherapy results, the right side shows the HbA1c reductions in various combinations with either metformin (MET), thiazolidinedione (TZD) or sulfonylurea (SU). In each study, the results for doses with 2.5 mg saxagliptin od (light bars) or 5 mg saxagliptin od (dark bars) are shown.
A larger study on the efficacy and safety of saxagliptin in type 2 diabetes patients with renal impairment is still ongoing. A meta-analysis of the existing phase 2 and phase 3 studies showed favorable cardiovascular outcomes in the saxagliptin-treated patients (see Figure 3). The development of saxagliptin as well as the other DPP-4 inhibitors emphasizes the advantages of DPP-4 inhibitors over classical insulin secretagogues (sulfonylureas and meglitinides) concerning their glucose-dependent action without intrinsic hypoglycemia risk and weight neutrality.

Saxagliptin has the advantage of having a very high selectivity towards DPP-4 and in comparison to sitagliptin and vildaglitpin it has a significantly higher potency to inhibit DPP-4 in vitro. These effects result in the low dose of the drug that has to be administered in type 2 diabetes therapy. Whether these in vitro data and the advantage of the low drug dose translate into a clinically meaningful difference to distinguish saxagliptin from the other DPP-4 inhibitors is not known yet. The head-to-head study comparing sitagliptin and saxagliptin has shown noninferiority for saxagliptin. The cardiovascular event rates from the combined study program carried out for the approval of saxagliptin are very favorable and have so far not been shown for the other DPP-4 inhibitors. In the long run, however, long-term efficacy and safety data are necessary to show the potential advantages of saxagliptin in comparison to other DPP-4 inhibitors.

Disclosures
The author is a member on advisory boards for AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Merck, Roche, and Takeda and has also received honoraria from these companies for giving lectures.

References


